Evidence map›Paper›PMID 40155990›Full record

ArticleCardio-oncology (London, England)2025

Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer.

Nishant P Shah, Avinash Singh, Tia Higano, Derya Tilki, Neil Fleshner, Paul Nguyen, Chris Plummer, Juan Gomez Rivas, Kathleen Zhang, Ricardo Rendon and 5 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nishant P ShahDuke Clinical Research Institute, P.O. Box 17969, Durham, NC, 27715, USA.
Avinash SinghDivision of Cardiology, East Carolina University, Greenville, NC, USA.
Tia HiganoDepartment of Urologic Sciences at the University of British Columbia, Vancouver, BC, Canada.
Derya TilkiMartini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Neil FleshnerDivision of Urology, University of Toronto, Toronto, ON, Canada.
Paul NguyenHarvard Medical School, Boston, MA, USA.
Chris PlummerFreeman Hospital, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Juan Gomez RivasHospital Clínico San Carlos, Madrid, Spain.
Kathleen ZhangDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Ricardo RendonDepartment of Urology, Dalhousie University, Halifax, NS, Canada.
Alicia MorgansDana-Farber Cancer Institute, Boston, MA, USA.
Filipe CirneDivision of Cardiology, East Carolina University, Greenville, NC, USA.
Darryl LeongDepartment of Medicine and Population Health Research Institute, McMaster University, Hamilton, Canada.
Daniel LenihanInternational Cardio-Oncology Society, Tampa, FL, USA.
Renato D LopesDuke Clinical Research Institute, P.O. Box 17969, Durham, NC, 27715, USA. renato.lopes@duke.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 1 million cases of prostate cancer are reported every year, and it is the second most common cancer in men. Androgen deprivation therapy (ADT) is a hallmark treatment for prostate cancer but is associated with the development or exacerbation of cardiovascular disease. The most common cause of non-cancer death in patients with prostate cancer is cardiovascular disease. Thus, a better understanding of the prevalence of cardiovascular toxicity across all therapies, management of potential cardiovascular complications, and prevention of cardiovascular events is essential as treatments continue to evolve. In this article, the first in a 2-part series, we provide a review of the current landscape of ADT therapy and its association with cardiovascular disease, summarize recent clinical trial data evaluating cardiovascular outcomes, and provide insights on the management of cardiovascular risk factors and adverse events for clinicians managing this high-risk population of men undergoing potentially cardiotoxic treatment for prostate cancer.

Indexed as

Androgen deprivation therapyCardiovascular diseasesHeart disease risk factorsProstate cancer

Identifiers

PMID40155990
PMCPMC11954300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.